The Role of Vaccination Centers in a National Mass Immunization Campaign—Policymaker Insights from the German COVID-19 Pandemic Vaccine Roll-Out
Author:
Danek Stella1, Achelrod Dmitrij2, Wichmann Ole3, Schwendicke Falk1ORCID
Affiliation:
1. Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral Diagnostics, Digital Health and Health Services Research, Assmannshauser Straβe 4-6, 14197 Berlin, Germany 2. Independent Researcher 3. Immunization Unit, Robert Koch Institute, 13353 Berlin, Germany
Abstract
During the COVID-19 vaccination campaign, Germany, like other high-income countries, introduced mass vaccination centers for administering vaccinations. This qualitative study aimed to examine the role that these novel, temporary government healthcare structures played in a mass immunization roll-out and how they can be optimally deployed. In addition, learnings for general emergency preparedness were explored. A total of 27 high-level policymakers responsible for planning and implementing the COVID vaccination campaign at the national and state level in Germany were interviewed in May and June 2022. The semi-structured interviews were analyzed using thematic analysis. Interviewees indicated that mass vaccination structures played an essential role with respect to controllability, throughput, accessibility and openness in line with the key success criteria vaccination coverage, speed and accessibility. In contrast to the regular vaccination structures (private medical practices and occupational health services), public administration has direct authority over mass vaccination centers, allowing for reliable vaccine access prioritization and documentation. The deployment of vaccination centers should be guided by vaccine availability and demand, and vaccine requirements related to logistics, as well as local capacities, i.e., public-health-service strength and the physician density, to ensure effective, timely and equitable access. Improvements to the capacity use, scalability and flexibility of governmental vaccination structures are warranted for future pandemics.
Funder
Charité—Universitätsmedizin Berlin
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference70 articles.
1. Bundeszentrale für gesundheitliche Aufklärung (BZgA) (2023, August 23). Das Impfsystem in Deutschland. Available online: https://www.impfen-info.de/wissenswertes/impfsystem-in-deutschland/. 2. Arbeitsweise und Empfehlungen der Ständigen Impfkommission (STIKO) im Kontext der COVID-19-Pandemie;Schlaberg;Bundesgesundheitsblatt Gesundh. Gesundh.,2022 3. German Federal Ministry of Health, Robert Koch-Institut, Bundeszentrale für Gesundheitliche Aufklärung, and Paul-Ehrlich-Institut (2021). National COVID-19 Vaccination Strategy—Version 2.0, German Federal Ministry of Health. 4. Gianfredi, V., Pennisi, F., Lume, A., Ricciardi, G.E., Minerva, M., Riccò, M., Odone, A., and Signorelli, C. (2021). Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature. Vaccines, 9. 5. (2023, August 23). German Infection Protection Act: § 20b IfSG valid until 12 December 2021. Available online: http://www.buzer.de/gesetz/2148/al162447-0.htm.
|
|